期刊文献+

插植调强近距离放射治疗复发性宫颈癌的临床研究 被引量:19

Inplanted intensity modulated brachytherapy for the recurred cervical carcinoma
原文传递
导出
摘要 为了探讨盆腔插植调强近距离放射治疗在复发性宫颈癌中的价值,选择25例盆腔复发性宫颈癌患者行插植后装调强近距离放疗为实验组,同期行常规后装放疗的25例盆腔复发性宫颈癌患者作为对照组,比较两组间的近期疗效及并发症。实验组CR20例,PR5例;对照组CR10例,PR7例,SD4例,PD4例,两组比较差异有统计学意义,P<0.005。实验组出现5例阴道直肠瘘,1例3级肠炎;对照组出现4例阴道直肠瘘,1例3级肠炎,两组比较差异无统计学意义,P>0.005。初步研究结果提示,盆腔插植调强近距离放射治疗复发性宫颈癌近期疗效满意,优于常规近距离放疗,毒副反应可耐受。 The objective of this study was to explore the value of pelvic inplanted intensity modulated brachytherapy for the recurred cervical carcinoma. A total of 50 patients of recurred cervical carcinoma were enrolled into the trial group(25 cases) which were treated by pelvic inplanted afterloading intensity modulated brachytherapy and the comparison group(25 cases) which were treated by the routine brachytherapy. There were 20 cases CR and 5 cases PR in the trial group,and 10 cases CR,7 cases PR,4 cases SD and 4 cases PD in the comparison group. The difference between the two groups is obvious (P〈0.05). There were 5 cases with and one cases with grade 3 enteritis,in trial group;and 4 cases with viginal-rectal fistula and 1 case with grade 3 enteritis in the comparison group. The pelvic inplanted intensity modulated brachytherapy for the recurred cervical carcinoma is satisfactory in the short time curative effect. It is better than the routine brachytherapy. Its late effect is tolerable.
出处 《中华肿瘤防治杂志》 CAS 2009年第18期1427-1429,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 宫颈肿瘤/治疗 近距离放疗 调强放疗 放射疗法 cervical neoplasms/therapy brachytherapy intensity modulated radiotherapy radiotherapy
  • 相关文献

参考文献13

  • 1Pettersson F. Annual report on the results of treatment in gynecological cancer[J]. Stockholm: FIGO, 1988,20.
  • 2Pettersson F. Annual report on the results of treatment in gynecological cancer[J]. Stockholm: FIGO, 1991,21.
  • 3黄永文,刘富元.晚期及复发子宫颈癌的处理[A].见曾益新,戎铁华.肿瘤学专题讲座[C].郑州:郑州大学出版社,2006:495-500.
  • 4杨晓霞,韩云青.24例复发宫颈癌的化疗疗效分析[J].医药论坛杂志,2005,26(9):32-33. 被引量:4
  • 5闻强,朱笕青.晚期或复发宫颈癌化疗进展[J].国外医学(妇产科学分册),2007,34(3):180-183. 被引量:8
  • 6Viswanathan A V. The Frank Ellis Memorial lecture: the use of three dimensional imaging in gynaecologieal radiation therapy [J]. Clinical Oncology, 2008,20 (1) : 1- 5.
  • 7Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from gynaecologieal (GYN) GEC-ESTRO working group (1): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005,74:235-245.
  • 8Tan L T, Coles C E, Hart C, et al. Clinical impact of computed tomography-based image-guided brachytherapy for cervix cancer using the tandem ring applicator-the addenbrooke's experience[J].Clinical Oncology, 2009,21 : 175-182.
  • 9Lessard E, Hsu I C, Pouliot J. Inverse planning for interstitial gynecologic template brachytherapy: truly anatomy-based planning[J]. Int J Radiat Oncol Biol Phys,2002,54(4):1243-1251.
  • 10Sharma D N, Subramani V, Rath G K, et al. Interstitial brachytherapy guided intensity modulated radiation therapy in cervical carcinoma: a dosimetric study. Proceedings of the 49th annual ASTRO meeting[J].Int J Radioation Ontology Biol Phys, 2007, 69(3) : 731- 732.

二级参考文献26

  • 1连利娟 林巧稚.妇科肿瘤学2版[M].北京:人民卫生出版社,1994.353.
  • 2Slchenm yer WJ, Row insky EK, Donehower RC, et al. The current status of camptothecin anatogues as antitum or agents. J National Cancer Institute, 1993,85 (4) :271.
  • 3Panayotis P. Preclinical studies of water insoluable camptothecin congeners, cytotoxicity, development of resistance,and combination treatment. Clinical Cancer Research,1995,1 : 1235.
  • 4Salecm A, Ibrablm N, Patel M, et al. Mechanism of resistance in a human cell the exposed to sequential topoismerese poisoning. Cancer Res, 1997,57 : 5100.
  • 5Megonigal MD, Fertala J, Bjornsti MA. Alteration in the catalytic activity of yeast DNA toposiomerase I result in cell cycle arrest and cel death. J B jol Chem, 1997,272:12801.
  • 6上海市药物研究所.羟基喜素硷的实验治疗和毒性[J].中国肿瘤临床,2000,27:37-37.
  • 7Fracasso PM,Blessing JA,Wolf J,et al.Phase Ⅱ evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix:a gynecologic oncology group study[J].Gynecol Oncol,2003,90(1):177-180.
  • 8Schilder RJ,Blessing JA,Morgan M,et al.Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix:a Phase Ⅱstudy of the gynecologic oncology group[J].Gynecol Oncol,2004,94(2):483-487.
  • 9Schilder RJ,Blessing J,Cohn DE,et al.Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix:a phase Ⅱ study of the Gynecologic Oncology Group[J].Gynecol Oncol,2005,96(1):103-107.
  • 10Muggia FM,Blessing JA,Method M,et al.Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix:a Gynecologic Oncology Group study[J].Gynecol Oncol,2004,92(2):639-643.

共引文献8

同被引文献171

引证文献19

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部